← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Eydis Bio, Inc.
Durham, NC
$6,615,113
Total funding
7
Grants
Funding over time
peak $1.9M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,615,113 · 7
By mechanism
R44$4,310,173 · 2
R43$1,074,950 · 2
R41$730,165 · 2
N43$499,825 · 1
Investigators at Eydis Bio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease$1,417,658
R44 · FY2025 · HL
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease$1,182,632
R44 · FY2024 · HL
Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis$913,097
R44 · FY2022 · AR
Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis$796,786
R44 · FY2021 · AR
Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's Disease$506,267
R41 · FY2024 · AG
Discovery and Development of Oral Small-molecule Direct-acting Antivirals$499,825
N43 · FY2025 · AI
Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain$480,955
R43 · FY2021 · NS
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation$309,288
R43 · FY2021 · HL
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation$284,707
R43 · FY2022 · HL
Improving the Oral Bioavailability and In vivo Efficacy of a Novel TAK1 Inhibitor Targeting Rheumatoid Arthritis$223,898
R41 · FY2019 · AR